An updated analysis of the low-density lipoprotein cholesterol (LDL-C) lowering drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, finds they are not cost-effective at current prices and that even greater ...
Aug 22, 2017
0
0
(HealthDay)—Five years after coronary-artery bypass grafting (CABG) surgery, patients whose operation was performed with cardiopulmonary bypass (on pump) lived longer than those whose surgeons performed the procedure without ...
Aug 18, 2017
0
0
(HealthDay)—For patients with an adverse reaction to a statin, continued statin prescriptions are associated with lower incidence of cardiovascular events and death, according to a study published online July 25 in the ...
Jul 25, 2017
0
0
Statins are known to reduce the risk of death and cardiovascular events for people who are at high risk; however, as many as 75 percent of patients discontinue statin therapy within two years, often after reporting an adverse ...
Jul 24, 2017
0
0
(HealthDay)—For asymptomatic patients with type 2 diabetes, the addition of coronary computed tomography angiography (CCTA)-detected obstructive coronary artery disease (CAD) improves prediction of major adverse cardiovascular ...
Jul 10, 2017
0
0
(HealthDay)—For acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) and receiving clopidogrel, prasugrel, or ticagrelor, ischemic outcome does not differ by gender, according to a ...
May 4, 2017
0
0
(HealthDay)—For adults presenting to the emergency department with chest pain, a single high-sensitivity assay for cardiac troponin T (hs-cTnT) below the limit of detection and a non-ischemic electrocardiogram (ECG) can ...
Apr 19, 2017
0
0
(HealthDay)—For patients undergoing dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with a drug-eluting stent (DES), DAPT cessation is significantly lower in patients with diabetes mellitus (DM), ...
Mar 29, 2017
0
0
New trial results show that in patients on statin therapy, the addition of evolocumab did not result in a significant change in cognitive function after 19 months of treatment.
Mar 19, 2017
0
0
A new class of cholesterol-lowering drug has been found to help patients cut their risk of cardiovascular disease, stroke and heart attack.
Mar 17, 2017
1
71
